B
Björn Dahlöf
Researcher at Sahlgrenska University Hospital
Publications - 408
Citations - 64668
Björn Dahlöf is an academic researcher from Sahlgrenska University Hospital. The author has contributed to research in topics: Left ventricular hypertrophy & Blood pressure. The author has an hindex of 96, co-authored 406 publications receiving 62129 citations. Previous affiliations of Björn Dahlöf include Veterans Health Administration & Cornell University.
Papers
More filters
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TL;DR: Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
Journal ArticleDOI
Guidelines for the management of atrial fibrillation
A. John Camm,Paulus Kirchhof,Gregory Lip,Ulrich Schotten,Irene Savelieva,Sabine Ernst,Isabelle C. Van Gelder,Nawwar Al-Attar,Gerhard Hindricks,Bernard Prendergast,Hein Heidbuchel,Ottavio Alfieri,Annalisa Angelini,Dan Atar,Paolo Colonna,Raffaele De Caterina,Johan De Sutter,Andreas Goette,Bulent Gorenek,Magnus Heldal,Stefan H. Hohloser,Philippe Kolh,Jean-Yves Le Heuzey,Piotr Ponikowski,Frans H. Rutten,Alec Vahanian,Angelo Auricchio,Jeroen J. Bax,Claudio Ceconi,Veronica Dean,Gerasimos Filippatos,Christian Funck-Brentano,Richard Hobbs,Peter Kearney,Theresa McDonagh,Bogdan A. Popescu,Zeljko Reiner,Udo Sechtem,Per Anton Sirnes,Michal Tendera,Panos E. Vardas,Petr Widimsky,Vazha Agladze,Etienne Aliot,Tosho L. Balabanski,Carina Blomström-Lundqvist,Alessandro Capucci,Harry J.G.M. Crijns,Björn Dahlöf,Thierry Folliguet,Michael Glikson,Marnix Goethals,Dietrich C. Gulba,Siew Yen Ho,Robert J.M. Klautz,Sedat Kose,John McMurray,Pasquale Perrone Filardi,Pekka Raatikainen,Maria Jesus Salvador,Martin J. Schalij,Alexander Shpektor,João de Sousa,Janina Stepinska,Hasso Uuetoa,José Luis Zamorano,Igor Zupan +66 more
TL;DR: Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means.
Journal ArticleDOI
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter S. Sever,Björn Dahlöf,Neil R Poulter,Hans Wedel,Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time, and may have implications for future lipid-lowering guidelines.
Journal ArticleDOI
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf,Peter S. Sever,Neil R Poulter,Hans Wedel,D Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol- based regimen, and these effects might not be entirely explained by better control of blood pressure.